Experimental scrutiny and project timelines: an example

N. Dooley, S. J. Ford, Elke Prasad, M. Elliott, Gavin Halbert

Research output: Contribution to journalArticlepeer-review

199 Downloads (Pure)


AZD0424 (Fig. 1) is a dual selective inhibitor of Src and Abl non-receptor tyrosine kinases being developed for clinical trial through a partnership between AstraZeneca and Cancer Research UK. Formulation, pre-formulation and development studies were performed at the Cancer Research UK Formulation Unit at the University of Strathclyde. Here the authors report an example where the proper use and interpretation of ‘forced degradation’ experiments (performed during the early development stages of a drug project) allowed analysts to quickly identify problems occurring at subsequent stages.
Original languageEnglish
Pages (from-to)1208-1209
Number of pages2
JournalJournal of Pharmacy and Pharmacology
Issue number10
Publication statusPublished - Oct 2010


  • tyrosine kinases
  • cancer research
  • experimental analysis


Dive into the research topics of 'Experimental scrutiny and project timelines: an example'. Together they form a unique fingerprint.

Cite this